Jacqueline Ramı́rez

5.0k total citations · 2 hit papers
77 papers, 3.8k citations indexed

About

Jacqueline Ramı́rez is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Jacqueline Ramı́rez has authored 77 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 42 papers in Oncology and 24 papers in Pharmacology. Recurrent topics in Jacqueline Ramı́rez's work include Cancer therapeutics and mechanisms (35 papers), Pharmacogenetics and Drug Metabolism (23 papers) and Lung Cancer Research Studies (13 papers). Jacqueline Ramı́rez is often cited by papers focused on Cancer therapeutics and mechanisms (35 papers), Pharmacogenetics and Drug Metabolism (23 papers) and Lung Cancer Research Studies (13 papers). Jacqueline Ramı́rez collaborates with scholars based in United States, China and Spain. Jacqueline Ramı́rez's co-authors include Mark J. Ratain, Federico Innocenti, Lalitha Iyer, Soma Das, Linda Janisch, Everett E. Vokes, Samir D. Undevia, Gini F. Fleming, Theodore Karrison and Charles M. Rudin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Jacqueline Ramı́rez

74 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

2004 695 citations Federico Innocenti, Samir D. Undevia et al. Journal of Clinical Oncology profile →
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

2002 521 citations Jacqueline Ramı́rez, Gini F. Fleming et al. profile →

Peers

Countries citing papers authored by Jacqueline Ramı́rez

Since Specialization

Citations

This map shows the geographic impact of Jacqueline Ramı́rez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline Ramı́rez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline Ramı́rez more than expected).

Fields of papers citing papers by Jacqueline Ramı́rez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline Ramı́rez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline Ramı́rez. The network helps show where Jacqueline Ramı́rez may publish in the future.

Co-authorship network of co-authors of Jacqueline Ramı́rez

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline Ramı́rez. A scholar is included among the top collaborators of Jacqueline Ramı́rez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline Ramı́rez. Jacqueline Ramı́rez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural basis for Lamassu-based antiviral immunity and its evolution from DNA repair machinery 2025 ·Proceedings of the National Academy of Sciences ·Matthieu Haudiquet, (unknown), Zhiying Zhang, Jacqueline Ramı́rez, (unknown), Paul Dominic B. Olinares, Rachel Lavenir, Mohammed Ahmed, M. Jason de la Cruz, Brian T. Chait, Samuel H. Sternberg, Aude Bernheim, Dinshaw J. Patel	0
2	The use of arts‐based methodologies and methods with young people with complex psychosocial needs: A systematic narrative review 2023 ·Health Expectations ·Sally Nathan, Michael Hodgins, (unknown), Jacqueline Ramı́rez, (unknown), Patricia Cullen	24
3	Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients 2020 ·The AAPS Journal ·(unknown), Amy S. Etheridge, Eleftheria Tsakalozou, Jacqueline Ramı́rez, Erika Cecchin, Ron H. N. van Schaik, Giuseppe Toffoli, Mark J. Ratain, Ron H.J. Mathijssen, Alan Forrest, Robert R. Bies, Federico Innocenti	4
4	Metabolism of megestrol acetate in vitro and the role of oxidative metabolites 2017 ·Xenobiotica ·Larry House, Michael J. Seminerio, Snezana Mirkov, Jacqueline Ramı́rez, Maxwell N. Skor, Joseph R. Sachleben, Masis Isikbay, Hari Singhal, Geoffrey L. Greene, Donald J. Vander Griend, Suzanne D. Conzen, Mark J. Ratain	5
5	P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA) 2016 ·Annals of Oncology ·Carles Pericay, Nieves Martínez Lago, (unknown), Ismael Macías, O. Donnay, (unknown), Beatriz García-Paredes, Jose Carlos Méndez, (unknown), Beatriz González-Astorga, (unknown), (unknown), Núria Rodríguez, (unknown), (unknown), Jacqueline Ramı́rez, Teresa Macarulla	1
6	In vitroglucuronidation of aprepitant: a moderate inhibitor of UGT2B7 2015 ·Xenobiotica ·Larry House, Jacqueline Ramı́rez, Michael J. Seminerio, Snezana Mirkov, Mark J. Ratain	8
7	Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs 2013 ·Clinical Cancer Research ·Kehua Wu, Larry House, Jacqueline Ramı́rez, Michael J. Seminerio, Mark J. Ratain	5
8	Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients 2012 ·Clinical Cancer Research ·Ezra E.W. Cohen, Kehua Wu, Christine Hartford, Masha Kocherginsky, (unknown), Yuanyuan Zha, (unknown), Michael L. Maitland, (unknown), (unknown), Larry House, Jacqueline Ramı́rez, Samir D. Undevia, Gini F. Fleming, Thomas F. Gajewski, Mark J. Ratain	51
9	Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non–Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions 2011 ·Cancer Research ·Wanqing Liu, Lijun He, Jacqueline Ramı́rez, Soundararajan Krishnaswamy, Rajani Kanteti, Yi‐Ching Wang, Ravi Salgia, Mark J. Ratain	36
10	Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue 2011 ·PLoS Genetics ·Federico Innocenti, Gregory M. Cooper, Ian B. Stanaway, Eric R. Gamazon, Joshua D. Smith, Snezana Mirkov, Jacqueline Ramı́rez, Wanqing Liu, Yvonne S. Lin, (unknown), (unknown), Nathan D. Trinklein, Erin G. Schuetz, Deborah A. Nickerson, Ken Thummel, Mark J. Rieder, Allan E. Rettie, Mark J. Ratain, Nancy J. Cox, Christopher D. Brown	134
11	Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors 2011 ·British Journal of Clinical Pharmacology ·Yong Liu, Jacqueline Ramı́rez, Mark J. Ratain	54
12	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole 2010 ·British Journal of Clinical Pharmacology ·Landry K. Kamdem, Yong Liu, Vered Stearns, Susan Kadlubar, Jacqueline Ramı́rez, Stacie C. Jeter, (unknown), Bryan A. Ward, Evan T. Ogburn, Mark J. Ratain, David A. Flockhart, Zeruesenay Desta	60
13	Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells 2009 ·Clinical Cancer Research ·Wanqing Liu, Lijun He, Jacqueline Ramı́rez, Mark J. Ratain	15
14	Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics 2009 ·Journal of Clinical Oncology ·Federico Innocenti, Deanna L. Kroetz, Erin G. Schuetz, M. Eileen Dolan, Jacqueline Ramı́rez, Mary V. Relling, Peixian Chen, Soma Das, Gary L. Rosner, Mark J. Ratain	200
15	A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours 2008 ·European Journal of Cancer ·Samir D. Undevia, Federico Innocenti, Jacqueline Ramı́rez, Larry House, Apurva A. Desai, (unknown), D. A. Singh, Theodore Karrison, Hedy L. Kindler, Mark J. Ratain	54
16	Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer 2007 ·Cancer Chemotherapy and Pharmacology ·Wei Peng Yong, Apurva A. Desai, Federico Innocenti, Jacqueline Ramı́rez, Dale R. Shepard, Ken Kobayashi, Larry House, Gini F. Fleming, Nicholas J. Vogelzang, Richard L. Schilsky, Mark J. Ratain	18
17	UGT1A128 genotype affects the in-vitro glucuronidation of thyroxine in human livers 2007 ·Pharmacogenetics and Genomics* ·(unknown), Jacqueline Ramı́rez, Federico Innocenti, Mark J. Ratain	23
18	Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes 2006 ·Pharmacogenetics and Genomics ·Jacqueline Ramı́rez, Bernard J. Komoroski, Snezana Mirkov, (unknown), Donna L. Fackenthal, Erin G. Schuetz, Soma Das, Mark J. Ratain, Federico Innocenti, Stephen C. Strom	18
19	A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital 2004 ·Clinical Pharmacology & Therapeutics ·Federico Innocenti, Samir D. Undevia, Jacqueline Ramı́rez, Shaila K. Mani, Richard L. Schilsky, N. J. Vogelzang, Marco A. M. Prado, Mark J. Ratain	38
20	Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns 1998 ·Journal of Chromatography B Biomedical Sciences and Applications ·(unknown), Jacqueline Ramı́rez, (unknown)	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact